5Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis , 2013, 13(9): 785-796.
6Zarkotou 0,Poumaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect, 2011,17(12):1798-1803.
7Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infec Dis, 2012, 55(7):943-950.
9Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother,2008 ,62(5):895-904.
10Patel RA, Gallagher JC. Drug fever. Pharmacotherapy, 2010, 30(1):57-69.
2Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethysulphate and drug directed Fe^2+ cleavage of 16S rRNA[J]. J Antimicrob Chemother, 2004, 53(4) :592-599.
3Rice LB. Challenges in identifying new antimicrobial agents effective for treating infection with Acinetobaeter baumannii and Pseudomonas aeruginosa [J]. Clin infect Dis,2006, 43 (Suppl 2) : S100 S105.
4Kelesidis T, Karageorgopoulos DE, Kelesidis I, et al. Tigecycline for the treatment of multidrug resistant Enterobacteriaceae : a systematic review of the evidence from microbiological and clinical studies[J]. J Antimicrob Chemother, 2008, 62(5) :895- 904.
5Baudry PJ, Nichol K, DeCorby M, et al. Comparison of antimicrobial resistance profiles among extended-spectrum-betalactamase producing and acquired AmpC beta lactanase-producing Escherichia coli isolates from Canadian intensive care units[J]. AntimicrobAgentsChemother, 2008, 52(5):1846-1849.
6Castanheira M, Sader HS, Deshpande LM, et al. Antimierobial activities of tigecycline and other broad speetrum antimicrobials tested against serine earbapenemase and metallo-β- laetamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program[J]. Antimicrob Agents Chemother, 2008, 52(2) :570- 573.
7Capone A, D'Arezzo S, Visca P, et al. In vitro activity of tigecycline against muhidrug resistant Acinetobacter baurnannii[J]. J Antimierob Chemother, 2008, 62(2) :422-425.
8Lolans K, Rice TW, Munoz-Price LS, et al. Muhicity outbreak of carbapenem-resistant Acinetobacter baumannii iso lates producing the carbapenemase OXA 40[J]. Antimicrob Agents Chemother, 2006, 50(9):2941-2945.
9Navon Venezia S, Leavitt A, Carmeli Y. High tigecycline resistant in multidrug-resistant Acinetohacter baumannii [ J ]. J Antimicroh Chemother, 2007, 59(4):772- 774.
10Denis O, Deplano A, Nonhoff C, et al. In vitro activities of ceftobiprole, tigecycline, daptomyein, and 19 other antimi crobials against raethicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals , Antimicrob Agents Chemother, 2006, 50(8): 2680-2685.
